William Blair downgraded Keros Therapeutics (KROS) to Market Perform from Outperform after the company voluntarily halted dosing in the 3.0 mg/kg and 4.5 mg/kg treatment arms in the ongoing TROPOS Phase 2 clinical trial of cibotercept in combination with background therapy in patients with pulmonary arterial hypertension, based on a safety review due to the unanticipated observation of pericardial effusion adverse events in the trial.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KROS:
- Keros Therapeutics downgraded to Neutral from Buy at BTIG
- Morning Movers: Keros Therapeutics plummets after halting TROPOS trial dosing
- Keros Therapeutics provides update on Phase 2 TROPOS trial
- Keros Therapeutics presents clinical data from Elritercept program at ASH
- Keros Therapeutics management to meet with Oppenheimer